Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.
about
The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Risk of osteoporosis and fracture incidence in patients on antipsychotic medication.Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.Antipsychotic-induced sexual dysfunction and its managementA review of the association between antipsychotic use and hyperprolactinaemia.Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder.Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review.Preliminary examination of microRNA expression profiling in bipolar disorder I patients during antipsychotic treatment.Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.Pharmacokinetic patterns of risperidone-associated adverse drug reactions.A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients.Clinical decision-making during 5 years of antipsychotic treatment.Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome.Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes.A Comment on "Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia".
P2860
Q33619940-9AC0E2D9-F842-47C7-BBAC-6E4E98628D6AQ34026011-A7D913B3-3432-4F77-94A2-6E79BF2252CAQ34037969-08EDE24D-496E-49F2-9F34-B0C153A7FD33Q36758151-A23E5A24-A20A-462A-B6BA-2E9B04FE67E7Q37162798-BE815D1D-7085-4A98-9D9C-920A20EEAE4FQ37162812-9DC06514-5F44-43E5-8034-1A670D0AE80AQ37747570-CA717FD7-B693-48A8-9A8F-CD17CE2AA38CQ38201749-79AE5ABD-1F76-43A1-84BA-E4B4DB7ACC9BQ38447364-9F421FFE-0465-4815-9A03-0C0B08530E3CQ38448948-B521ACA0-01F4-4882-BEDA-453F862D8372Q38989642-E3A3CA9D-FCE5-4B37-AAB4-371E3B92CACCQ39633628-185F4461-2C52-4CB3-BE51-716C62131D0BQ43262223-3C88A8FE-2F45-477B-8465-55FC5F780B24Q43489252-1F97E235-0273-47CF-A167-CBC68BBAB5EAQ46937650-38CC5EFB-05B9-4043-BD3F-CE7D493EFF05Q46937654-DE2B7032-8960-47AF-9375-78DD616A950BQ50794596-22B44B5B-2488-473D-A8C5-972CF4DFAD74Q55009521-BC6DB873-EB55-4A83-B5E9-501A431A8B6D
P2860
Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prolactin level during 5 years ...... ents with psychotic disorders.
@en
Prolactin level during 5 years ...... ents with psychotic disorders.
@nl
type
label
Prolactin level during 5 years ...... ents with psychotic disorders.
@en
Prolactin level during 5 years ...... ents with psychotic disorders.
@nl
prefLabel
Prolactin level during 5 years ...... ents with psychotic disorders.
@en
Prolactin level during 5 years ...... ents with psychotic disorders.
@nl
P2093
P2860
P1476
Prolactin level during 5 years ...... ents with psychotic disorders.
@en
P2093
Eberhard J
Lindström E
P2860
P304
P356
10.1111/J.1600-0447.2006.00897.X
P407
P577
2007-04-01T00:00:00Z